E. I. Khatkova

E. I. Khatkova

Auto-generated profile, based on publicly available information

E. I. Khatkova

A. S. Loginov Moscow Clinical Scientific Center, Moscow Healthcare Department

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 January 2023 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
YVYu. A. Vasyuk
Yu. A. Vasyuk
ESE. Y. Shupenina
E. Y. Shupenina
ENE. O. Novosel
E. O. Novosel
DVD. A. Vyzhigin
D. A. Vyzhigin
ANA. G. Nosova
A. G. Nosova
ЮВЮ. А. Васюк
Ю. А. Васюк
Aim. To search early signs of cardiotoxicity in patients receiving anticancer therapy and evaluate the effectiveness of cardioprotection with an angiotensin-converting enzyme inhibitor, beta-blocker and myocardial cytoprotector.Material and methods. The study included 98 patients with high and very high risk of cardiotoxicity according to the Mayo Clinic scale (USA). Cancer patients with hypertension were offered cardioprotective treatment with a fixed-dose combination of perindopril and bisoprolol, and patients with very high risk and concomitant coronary artery disease additionally trimetazidine.The patients were divided into 2 following groups: the experimental group (n=50), where patients were prescribed cardioprotective therapy, and the control group (n=48), which consisted of patients who refused or had contraindications to cardioprotection. All patients underwent an examination, including the collection of complaints and anamnesis, physical examination, electrocardiography and echocardiography with an assessment of left ventricular (LV) global longitudinal strain before chemotherapy and 1, 3, 6, 9 and 12 months after initiation of anticancer therapy.Results. In patients of the control group, by the end of the follow-up, the left atrial volume index and LV end-diastolic volume index significantly increased. In the main group, these indicators did not change significantly. In the control group, by the final visit, the LV ejection fraction significantly decreased in comparison with the initial value and the value in the first group. After 6, 9 and 12 months, there was a significant decrease in the LV global longitudinal strain in the control group, while in the main group this indicator remained within the normal range. The mortality rate in the control group was significantly higher (15% vs 2% in the experimental group). In the experimental group, cardiotoxic complications occurred in 28%, while in the control group — in 78% of patients.Conclusion. The study demonstrated the significant importance of cardiac monitoring and primary drug prevention of cardiotoxicity of anticancer therapy. A sig nificant deterioration in LV systolic function was shown in patients with a high and very high risk of cardiotoxicity who did not receive cardioprotective therapy, while its high efficiency was demonstrated in patients of the experimental group.

10 December 2021 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
DFD. A. Filonenko
D. A. Filonenko
TIT. M. Ibragimova
T. M. Ibragimova
NPN. I. Polshina
N. I. Polshina
ABA. V. Belogurova
A. V. Belogurova
EKE. I. Khatkova
E. I. Khatkova
LZLiudmila Zhukova
Liudmila Zhukova
Introduction. Сombination of alpelisib plus fulvestrant is approved in patients with hormone receptor positive, HER2-negative, PIK3CA-mutated advanced breast cancer (ABC) after progression on hormonotherapy. Efficacy data of alpelisib in heavily pretreated patients with HR+/HER-2-, PIK3CA-mutated advanced breast cancer are limited, only results from phase I trial are available. Here we report our results of alpelisib efficacy in 19 heavily pretreated patients.Object: to evaluate efficacy and safety of combination alpelisib plus fulvestrant in patients with HR+/HER2-, PIK3CA-mutated advanced breast cancer in initial and later lines of therapy in real clinical practice.Materials and methods. Combination of alpelisib plus fulvestrant was investigated in 19 patients with HR+/HER2-, PIK3CAmutated ABC, alpelisib at a dose of 300 mg per day plus fulvestrant at a dose of 500 mg i.m. every 28 days and once on day 15. Treatment continued until disease progression or unacceptable toxicity.Results. From February 2021 19 patients with HR+/HER2-, PIK3CA-mutated advanced breast cancer were treated with alpelisib plus fulvestrant. The data cut off is October 2021. Median lines of treatment in advanced disease was five, including 19 (100%) patients received CDK4/6, 14 (74%) – fulvestrant and/or everolimus and 15 (79%) – chemotherapy. 4 (21%) received alpelisib in a second line, 15 (79%) – in subsequent lines. Median progression-free survival was 7 months. The response was evaluated in 18 patients: partial response was achieved in 5 (28%) patients, stable disease – in 9 (50%), disease progression – 4 (22%). The most frequent adverse events were hyperglycemia – 74% (grade 3 – 22%), creatinine increased – 42% and rash – 37% (grade 3 – 22%). Only one patient has discontinued the treatment due to Quincke`s edema.Conclusions. Combination of alpelisib with fulvestrant is an effective option both in initial and later lines of therapy in patients with HR+/HER2-, PIK3CA-mutated advanced breast cancer including fulvestrant, CDK4/6 inhibitors and/or everolimus – pretreated patients.

21 December 2020 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
LZLiudmila Zhukova
Liudmila Zhukova
EKE. I. Khatkova
E. I. Khatkova
IGI. P. Ganshina
I. P. Ganshina
IKI. V. Kolyadina
I. V. Kolyadina
ELE. V. Lubennikova
E. V. Lubennikova
Understanding of cancer biology is at the cornerstone of design of new and effective treatment strategies. Identification of molecular drivers of tumor growth and progression allow identify right patient for the right treatment for personalized treatment plan optimization. Breast cancer (BC) encompasses a heterogeneous collection of neoplasms with diverse morphologies, molecular phenotypes, responses to therapy, probabilities of relapse and overall survival. Molecular and histopathological classification aims to categories tumors into subgroups to inform clinical decisions, to improve long-term treatment results and maintain the quality of life of this group of patients. Germinal mutation in the BRCA1/2 (BRCAm) genes in a tumor determines the hereditary predisposition, disease manifestation, therapeutic options and clinical efficacy. Therefore, patients withBRCAmBCrepresent a special subgroup requiring personalized treatment approach.Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, is a targeted therapeutic agent that acts as inhibitor of single-strand breaks reparation, leading to their accumulation, conversion to double-strand breaks and eventually to cancer cell apoptosis. Olaparib is a first-in-class PARP-inhibitor with an outstanding antineoplastic activity known for some malignant tumors, demonstrates effectiveness and safety of therapy inBRCAmBCas well. The results of OlympiAD and LUCY trials are represented in the article. Subgroup analysis may define the patient population that would benefit from PARP inhibitors therapy.

22 January 2025 in Malignant tumours
Verified
Journal Article
Open access
PDF file
LZLiudmila Zhukova
Liudmila Zhukova
KGKaterina S. Grechukhina
Katerina S. Grechukhina
EKE. I. Khatkova
E. I. Khatkova
AAA. A. Akopyan
A. A. Akopyan
MVM. V. Volkonskii
M. V. Volkonskii
AYA. N. Yurchenkov
A. N. Yurchenkov
Introduction: The systemic therapy of patients with metastatic luminal HER2‑negative breast cancer (mBC) in‑ cludes various options, which can be fundamentally divided into endocrine therapy and chemotherapy. According to the Clinical Guidelines, both international and Russian, the “gold standard” of the 1st line therapy for patients with metastatic luminal HER2‑negative breast cancer (mBC) is a combination of cyclindependent kinase inhib‑ itors 4 / 6 (iCDK4 / 6) with endocrine therapy (ET). However, until recently we did not have complete data on the characteristics of the Russian population of patients with luminal HER2‑breast cancer, their treatment options, and the results of this therapy.Aim: To analyze the patients’ profile and current treatment approaches for patients with luminal HER2 mBC in routine clinical practice in Moscow.Materials and methods: The study was performed as an observational, crosssectional and retrospective study. The data of 2,500 patients from medical institutions in Moscow who received systemic therapy for luminal HER2 mBC in AugustOctober 2021 were analyzed.Results: The largest number of patients received iCDK4 / 6 + ET in the first and second lines: 69.0 % and 52.0 %, respectively. In the first line, 54.6 % of patients received ribociclib, 43.1 % palbociclib and 2.3 % abemaciclib. In the second line, 50.6 % of patients received ribociclib, 47.8 % palbociclib and 1.6 % abemaciclib. As the pretreatment of patients increased, preference was given to other treatment methods, therefore the proportion of combined ET decreased to 34.0 % in the third line and 25.0 % in the fourth and subsequent lines.Conclusion: The data obtained indicate that the appointment of iCDK4 / 6 + ET is made in accordance with the Clinical Guidelines for the treatment of breast cancer of the Ministry of Health of the Russian Federation from 2021 and the preferred firstline treatment option for patients with luminal HER2 mBC in Moscow is combined endocrine therapy.

1 January 2022 in CLINICAL AND EXPERIMENTAL MORPHOLOGY
Verified
Journal Article
Closed access
MCMoscow A.S. Loginov Moscow Clinical Scientific Center
Moscow A.S. Loginov Moscow Clinical Scientific Center
ITI.M. Telezhnikova
I.M. Telezhnikova
LZLiudmila Zhukova
Liudmila Zhukova
VKVlada Kometova
Vlada Kometova
SKSERGEY KHOMERIKI
SERGEY KHOMERIKI
GSG.R. Setdikova
G.R. Setdikova
Introduction. Neoadjuvant therapy (NAT) provides an in vivo assessment of primary tumor sensitivity to systemic therapy. However, the data on Ki67 clinical significance as a prognostic factor for the effectiveness of chemotherapy in breast cancer (BC) cause controversy. The International Ki67 Interpretation Workgroup for Breast Cancer (IKWG) meeting held in October 2019, recommended developing a standardized methodology for visual global scoring, which is proposed to be used in clinical practice. The aim of the study was to assess the clinical significance of Ki67 using visual global scoring in BC. Materials and methods. The study included 32 patients with proven BC that received preoperative neoadjuvant therapy. We studied paraffin histological blocks, analyzed the Ki67 expression over time in patients with residual tumors, and assessed the correlations of clinical and morphological signs before treatment. Ki67 was determined as the overall average with global scoring. The Ki67 scoring app for smartphones was used as an auxiliary tool to increase the accuracy. Results. The median value of the Ki67 index before NAT was 75.0% (34.8–85.0) and after the therapy it was 1.0% (0.0–6.2) [p<0.0001]. The Ki67 value was significantly lower (p=0.0077) [36% (30–75)] in the presence of residual tumor compared to that in patients without it [85% (78.8–90)]. Conclusion. The Ki67 index before NAT is a strongly prognostic factor of its effectiveness. The research of the Ki67 marker for concomitant diagnosis, which showed prognostic Ki67 role, can be considered as a correct diagnostic vector, only if strict analytical validity is observed. Keywords: Ki67, breast cancer, neoadjuvant therapy, global scoring, IKWG, Ki67 scoring app